J. O’Shaughnessy

1.8k total citations
50 papers, 1.1k citations indexed

About

J. O’Shaughnessy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. O’Shaughnessy has authored 50 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in J. O’Shaughnessy's work include Cancer Treatment and Pharmacology (28 papers), Advanced Breast Cancer Therapies (25 papers) and HER2/EGFR in Cancer Research (16 papers). J. O’Shaughnessy is often cited by papers focused on Cancer Treatment and Pharmacology (28 papers), Advanced Breast Cancer Therapies (25 papers) and HER2/EGFR in Cancer Research (16 papers). J. O’Shaughnessy collaborates with scholars based in United States, Spain and Germany. J. O’Shaughnessy's co-authors include Ronald Berenson, Cynthia E. Dunbar, Michele Cottler‐Fox, RC Moen, S Doren, Jay J. Greenblatt, FM Stewart, Éric Charpentier, Supriya Gupta and Anne Blackwood‐Chirchir and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

J. O’Shaughnessy

47 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. O’Shaughnessy United States	12	747	402	335	272	189	50	1.1k
Éric Charpentier United States	15	652 0.9×	401 1.0×	107 0.3×	178 0.7×	164 0.9×	22	1.0k
Oday Hamid United States	15	685 0.9×	669 1.7×	111 0.3×	123 0.5×	201 1.1×	41	1.2k
Julian Schardt Switzerland	13	369 0.5×	468 1.2×	175 0.5×	392 1.4×	114 0.6×	26	1.1k
Francesco Favero Denmark	8	668 0.9×	679 1.7×	178 0.5×	725 2.7×	350 1.9×	10	1.4k
Therese Törngren Sweden	15	605 0.8×	555 1.4×	295 0.9×	313 1.2×	154 0.8×	26	1.1k
Jennifer D. Thompson United States	8	392 0.5×	405 1.0×	543 1.6×	308 1.1×	68 0.4×	11	1.2k
Beth A. Hellerstedt United States	14	557 0.7×	314 0.8×	96 0.3×	267 1.0×	316 1.7×	32	1.0k
NE Davidson United States	6	542 0.7×	169 0.4×	92 0.3×	275 1.0×	96 0.5×	15	787
Grzegorz Rymkiewicz Poland	15	641 0.9×	245 0.6×	147 0.4×	350 1.3×	109 0.6×	63	1.1k
Alex Pearson United Kingdom	9	918 1.2×	470 1.2×	142 0.4×	537 2.0×	823 4.4×	16	1.5k

Countries citing papers authored by J. O’Shaughnessy

Since Specialization

Citations

This map shows the geographic impact of J. O’Shaughnessy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. O’Shaughnessy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. O’Shaughnessy more than expected).

Fields of papers citing papers by J. O’Shaughnessy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. O’Shaughnessy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. O’Shaughnessy. The network helps show where J. O’Shaughnessy may publish in the future.

Co-authorship network of co-authors of J. O’Shaughnessy

This figure shows the co-authorship network connecting the top 25 collaborators of J. O’Shaughnessy. A scholar is included among the top collaborators of J. O’Shaughnessy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. O’Shaughnessy. J. O’Shaughnessy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manich, C. Saura, LA Carey, J. O’Shaughnessy, et al.. (2025). 297O Imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): A subgroup analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) from EMBER-3. ESMO Open. 10. 104869–104869.

O’Shaughnessy, J., et al.. (2024). 369P Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study. Annals of Oncology. 35. S372–S373. 2 indexed citations

Barrios, Carlos H., Nadia Harbeck, Gabriel N. Hortobágyi, et al.. (2024). 113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). ESMO Open. 9. 103101–103101. 2 indexed citations

Huober, J., et al.. (2024). Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer. Clinical Breast Cancer. 25(4). 307–324.

Harbeck, Nadia, Priya Rastogi, J. O’Shaughnessy, et al.. (2023). LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Annals of Oncology. 34. S1256–S1256. 11 indexed citations

Lüftner, Diana, et al.. (2023). 98P Real-world effectiveness and safety of neratinib in the extended adjuvant treatment of patients with HER2+ early breast cancer (eBC) in the United States community oncology setting. ESMO Open. 8(1). 101322–101322. 1 indexed citations

Bardia, Aditya, Gabriel N. Hortobágyi, Oleg Lipatov, et al.. (2023). LBA23 Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC). Annals of Oncology. 34. S1261–S1262.

Johnston, Stephen, Nadia Harbeck, Roberto Hegg, et al.. (2020). LBA5_PR Abemaciclib in high risk early breast cancer. Annals of Oncology. 31. S1143–S1144. 2 indexed citations

Johnston, S., Nadia Harbeck, Roberto Hegg, et al.. (2020). 2MO Abemaciclib in high risk early breast cancer. Annals of Oncology. 31. S1242–S1243. 2 indexed citations

10.

Martin, Michael, Suzette Delaloge, Luc Dirix, et al.. (2013). Abstract OT2-6-07: Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebo-controlled study – BELLE-4. Cancer Research. 73(24_Supplement). OT2–6. 3 indexed citations

11.

George, Timothy, Stefan Krüger, Anne Favret, et al.. (2012). Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Annals of Oncology. 23(10). 2599–2605. 6 indexed citations

12.

Buzdar, Aman U., Binghe Xu, Raghunadharao Digumarti, et al.. (2011). Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Annals of Oncology. 23(3). 589–597. 11 indexed citations

13.

Wu, Yun, Mayur M. Amonkar, Beth Sherrill, et al.. (2011). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of Oncology. 22(12). 2582–2590. 23 indexed citations

14.

Espina, Virginia, et al.. (2011). P5-13-03: Correlation of Clinical and Molecular Findings with Pathologic Response to Preoperative Lapatinib and Trastuzumab, Separately or in Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer.. Cancer Research. 71(24_Supplement). P5–13. 4 indexed citations

15.

Pippen, John, Devchand Paul, Christopher Stokoe, et al.. (2011). Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.. Journal of Clinical Oncology. 29(15_suppl). 500–500. 9 indexed citations

16.

O’Shaughnessy, J., Véronique Dièras, & Stephen Chan. (2010). 475 Consistent progression-free survival benefit of capecitabine-bevacizumab in all prespecified subgroups of the RIBBON-1 study in patients with metastatic breast cancer (MBC). European Journal of Cancer Supplements. 8(3). 198–198. 1 indexed citations

17.

Glück, Stefan, et al.. (2009). Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): An exploratory data analysis. Journal of Clinical Oncology. 27(15_suppl). 1024–1024. 6 indexed citations

18.

Jones, Stephen E., Ruth Oratz, Devchand Paul, et al.. (2009). Cardiac Safety Results of a Phase II Trial of Adjuvant Docetaxel/Cyclophosphamide Plus Trastuzumab (Her TC) in HER2+ Early Stage Breast Cancer Patients.. Cancer Research. 69(24_Supplement). 5082–5082. 2 indexed citations

19.

Schwartz, Gretchen N., Frances T. Hakim, J. Zujewski, et al.. (1996). Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow. British Journal of Haematology. 92(3). 537–547. 9 indexed citations

20.

O’Shaughnessy, J., et al.. (1993). Phase I study of taxol plus doxorubicin plus granulocyte colony-stimulating factor (G-CSF) in patients with metastatic breast cancer. European Journal of Cancer. 29. S117–S117. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact